Omada Health to present RWE on behavior change program at ObesityWeek

Omada Health (OMDA) will present two posters at ObesityWeek 2025 highlighting the potential impact of Omada’s behavior change program on members currently or previously on GLP-1 medications for weight loss. Together, these analyses suggest that engagement with Omada may enhance results for members who have been on GLP-1s for weight loss, whether they stay on the medication or not. Previous clinical studies have suggested that sustained weight loss leads to increased long-term health benefits, including the reduction of comorbidities, and persistence on a GLP-1 is associated with greater weight loss. Those who stop GLP-1s tend to regain the weight they lost on the medication. Omada’s analyses demonstrated the clinical benefit of its wraparound lifestyle program on members at various stages of GLP-1 usage. Omada Increased GLP-1 Medication Persistence and Weight Loss: The first analysis examined GLP-1 persistence rates of 1,124 Omada members enrolled in Omada’s Enhanced GLP-1 Care Track, which provides tailored support to members on their GLP-1 journey. The analysis evaluated Omada members at 12 and 24 weeks in the program, examining how factors such as program engagement impacted members’ medication persistence. While real-world evidence has previously found lower GLP-1 persistence rates compared to clinical trials, Omada’s analysis demonstrated that support via Omada’s program supported enhanced persistence commensurate with increased engagement; 84% of participants stayed on their medication for 24 weeks and lost more weight than those who stopped earlier. It also found that for every 10 additional engagements per week in the initial 12 weeks, the odds of medication persistence were 54% higher. Omada Members Maintained Sustained Weight Lost 12 months Post-Discontinuation: The second analysis looked at weight change during the discontinuation phase of the GLP-1 journey. The team conducted a retrospective analysis using prescription claims to examine 816 total Omada members without type 2 diabetes, evaluating them at 6, 9, and/or 12 months after GLP-1 discontinuation. It found that, at one year post-discontinuation, members experienced 0.8% average weight change, compared to 11-12% weight gain typically seen in clinical trials, with 63.2% maintaining or continuing to lose weight at 12 months.